

C2
D1 35. (Amended) A fragment of a monoclonal antibody generated by hybridoma HBL106,
deposited under ATCC Accession No. HB11483, that specifically binds to an ACT-4-h-1 receptor
polypeptide.

C3
D1 60. (Amended) A fragment of an L106 antibody that specifically binds to an ACT-4-h-1
receptor polypeptide with a binding affinity of at least 10^7 M, wherein said L106 antibody is
produced by hybridoma HBL106, deposited under ATCC accession No. HB11483.

C4
D1 64. (Amended) A humanized antibody which binds to an ACT-4 receptor polypeptide
comprising a humanized heavy chain, wherein the humanized heavy chain comprises three
complementarity determining regions corresponding to the complementarity determining regions of
an L106 antibody heavy chain, wherein said L106 antibody is produced by hybridoma HBL106,
deposited under ATCC accession No. HB11483.

C5
D1 67. (Amended) A humanized antibody which binds to an ACT-4 receptor polypeptide
comprising a humanized light chain, wherein the humanized light chain comprises three
complementarity determining regions corresponding to the complementarity determining regions of
an L106 antibody light chain, wherein said L106 antibody is produced by hybridoma HBL106,
deposited under ATCC accession No. HB11483.

C6
D1 70. (Amended) A humanized antibody which binds to an ACT-4 receptor polypeptide
comprising (a) a humanized light chain, wherein the humanized light chain comprises three

complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody light chain, and (b) a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody heavy chain, wherein said L106 antibody is produced by hybridoma HBL106, deposited under ATCC accession No. HB11483.

Please add the following new claims 78-91:

--78. (New) An immunotoxin comprising the antibody of claim 59 fused to a toxin polypeptide.

--79. (New) A monoclonal antibody that specifically binds to ACT-4-h-1 receptor polypeptide.

--80. (New) An immunotoxin comprising the antibody of claim 79 fused to a toxin polypeptide.

--81. (New) A fragment of the antibody of a monoclonal antibody that specifically binds to ACT-4-h-1 receptor polypeptide.--

--82. (New) The fragment of claim 81, wherein said fragment is selected from the group consisting of a heavy chain, a light chain, a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, a Fabc fragment, and a Fv fragment.

~~83.~~ (New) A humanized antibody which binds to an ACT-4-h-1 receptor polypeptide comprising a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of the heavy chain of a monoclonal antibody that specifically binds to ACT-4-h-1 receptor polypeptide. ~~1~~

~~84.~~ (New) The humanized antibody of claim 83, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-fold of the binding affinity of an L106 antibody, produced by hybridoma HBL106, deposited under

ATCC Accession No. HB11483.--

~~85.~~ (New) A fragment of a humanized antibody which binds to an ACT-4-h-1 receptor polypeptide comprising a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of the heavy chain of a monoclonal antibody that specifically binds to ACT-4-h-1 receptor polypeptide, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide. ~~m~~

~~86.~~ (New) A humanized antibody which binds to ACT-4-h-1 receptor polypeptide comprising a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a light chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide. ~~v~~

87. (New) A fragment of a humanized antibody which binds to ACT-4-h-1 receptor polypeptide comprising a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a light chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide.

88. (New) The humanized antibody of claim 86, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-fold of the binding affinity of an L106 antibody, produced by hybridoma HBL106, deposited under ATCC Accession No. HB11483.

89. (New) A humanized antibody which binds to ACT-4-h-1 receptor polypeptide comprising (a) a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a light chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide, and (b) a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a heavy chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide.

90. (New) The humanized antibody of claim 89, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-

fold of the binding affinity of an L106 antibody produced by hybridoma HBL106, deposited under ATCC Accession No. HB11483. ~~#~~

~~#~~91. (New) A fragment of a humanized antibody which binds to ACT-4-h-1 receptor polypeptide comprising (a) a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a light chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide, and (b) a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of a heavy chain of an antibody that specifically binds to ACT-4-h-1 receptor polypeptide, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide. ~~#~~
